E Fund ETFs Trust - E Fund (HK) Solactive Biopharma Select Index ETF
No trades
No trades
Key stats
Fund info
Home page
Inception date
Mar 23, 2026
Replication method
Physical
Primary advisor
E Fund Management (Hong Kong) Co., Ltd.
ISIN
HK0001254553
FIGI
BBG020W6RCF6
Identifiers
ISIN HK0001254553
The investment objective is to provide investment results that, before fees and expenses, closely correspond to the performance of the Solactive Biopharma Select Index (the Index).
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.78%
Health Technology99.78%
Bonds, Cash & Other0.22%
Cash0.22%
Breakdown by region
Asia57.64%
North America30.09%
Europe11.65%
Middle East0.63%
Latin America0.00%
Africa0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently asked questions
3186 top holdings are Keymed Biosciences, Inc. and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H, occupying 3.33% and 3.11% of the portfolio correspondingly.
3186 assets under management is 25.55 M HKD. It's fallen 12.15% over the last month.
3186 fund flows account for 3.93 M HKD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
No, 3186 doesn't pay dividends to its holders.
3186 shares are issued by E Fund Management Co., Ltd. under the brand E Fund. The ETF was launched on Mar 23, 2026, and its management style is Passive.
3186 follows the Solactive Biopharma Select Index - HKD - Benchmark TR Net. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
3186 invests in stocks.
3186 trades at a premium (0.21%) meaning the ETF is trading at a higher price than the calculated NAV.